NitroAlbmin - A non invasive biomarker of early stage nitro-oxidative stress

A non invasive biomarker of early stage nitro-oxidative stress : Nitrated Plasma Albumin

Ref : TO B076​

Avantages concurentiels

  • First clinically validated marker of nitrative stress available​
  • Simple, specific, quick and sensitive (detection of nitroalbumin even in populations with low levels, such as newborns)​
  • Clinically validated in several pathologies​
  • Suitable for use with plasma, serum, cerebrospinal fluid and urine​
  • Antibodies suitable for use in cells and tissues by Western-blot and immunoprecipitation​

opportunités de marché

  • Research and preclinical studies​
  • Clinical studies (diabetes, neurodegenerative diseases, inflammation, infectious diseases, respiratory diseases (COPD), cancer, toxicology, …)​
  • Follow up of treatment (i.e. neuroprotective strategies aiming at scavenging ONOO or preventing the generation of its precursors​)
  • Cosmetology ​

Stade de développement

  • 1st generation ELISA (anti-nitrotyrosine mAb + anti-albumin-HRP pAb) developed and clinically validated on newborns suffering from asphyxia or hypoglycemia​
  • Anti-nitroalbumin mAbs (against the nitrated 138Tyr containing epitope of human albumin) generated to develop a second-generation ELISA​

TRL3

Partenariat recherché

  • Licensing
  • Collaborative research​

Propriété intellectuelle

Patent application : WO/2009/112670​

Chercheur / Laboratoire

Serge Bottari, Institute for advanced Biosciences (IAB)

Présentation

Increased production of reactive oxygen (ROS) and reactive nitrogen species (RNS), and subsequent nitro-oxidative stress, is associated with many pathogical conditions such as neurodegenerative diseases, cancer, diabetes, respiratory, cardiovascular, infectious and inflammatory diseases. ​

Whereas numerous (> 70) markers of oxidative stress are available, there are so far no reliable assays allowing the investigation of nitrative stress in research and clinical practice.​

Tyrosine nitration is among the earliest markers of nitro-oxidative stress. Detection of these early and reversible events may therefore allow for a better understanding of pathophysiological processes and for the early implementation and follow-up of treatments.​

The present invention relates to the development of a quantitative immunoassay and reagents for a known well-characterized nitrated plasma protein, nitroalbumin. This biomarker has been clinically validated in perpartal hypoxia and neonatal hypoglycemia.​

TECHNOLOGY DETAILS​

With the half-life of ONOO- being less than 1s in vivo, it is impossible to measure its concentration directly. Systemic nitro-oxidative stress can therefore only be determined by measuring the degree of nitration of a stable plasma protein with a sufficient half-life and a known number of nitration sites.​

How it works:

  • ELISA for the quantitative determination of nitroalbumin in human plasma: robust and highly sensitive method for monitoring nitroalbumin concentrations even in populations which display low levels, such as newborns​
  • Affinity-purified anti-nitrotyrosine and anti-albumin antibodies warrant the specificity of the assay: lack of significant cross-reactivity with other tyrosine adducts, 5-nitrotryptophan, native human albumin, and aminotyrosine-albumin.


Applications

In addition to licensing, the technology is available through collaborative research opportunities with the inventors for further development such as:

  • The development of a 2nd generation ELISA using proprietary anti-nitroalbumin mAbs combined or not with anti-albumin Abs to improve the linearity of the assay​
  • Clinical validation in relevant pathologies: COPD, neurodegenerative diseases diabetes, …

Suivez l'actualité de Floralis

Inscrivez-vous pour recevoir notre newsletter.

Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous continuez à utiliser ce dernier, nous considérerons que vous acceptez l'utilisation des cookies. En savoir plus OK